Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Genkyotex. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Genkyotex's earnings available for a low price, and how does
this compare to other companies in the same industry?
Genkyotex's earnings are expected to grow by 9.4% yearly, however this is not considered high growth (20% yearly).
Genkyotex's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Genkyotex's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Ilias Papatheodorou also known as Elias, has been the Chief Executive Officer at Genkyotex S.A. since September 30, 2015 and serves as its Director. Mr. Papatheodorou served as Chief Business Officer of Genkyotex S.A. from March 2015 to September 30, 2015. Mr. Papatheodorou served as the Chief Business Officer of Covagen AG since April 15, 2013 and was instrumental in the closing of a CHF46 million series B round and in the subsequent sale of Covagen to Jannsen Pharmaceuticals, a J&J Company. Mr. Papatheodorou served as a Senior Vice President of Business Development and Vice President of Business Development and operations at MediGene AG, where he negotiated the original deal between Medigene and Syncore. He served as Chief Executive Officer at Novosom AG. He joined novosom AG in September 2004. He has 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements. Mr. Papatheodorou served as Vice President of marketing, sales and business development at ATI Medical Imaging. During his tenure, signed multi-million agreements with companies such as Amgen, Janssen, J&J, Medicus, Medtronic, Novartis, CBS, Discovery Network as well as collaborations agreements with the NIH, Siemens Medical and Zeiss. Mr. Papatheodorou was also involved in discussions with a number of leading pharmaceutical and biotechnology companies. Prior to ATI, he worked in various positions for The Coca-Cola Company and Philip Morris Inc. In his tenure the Smarticles technology entered clinical trials in the U.S.A., Smarticles technology raised funds and closed licensing deals with Isis Pharmaceuticals (NASDAQ: ISIS) and ProNAi Therapeutics. He serves as the Head of the Board of Priaxon AG and as Board member of Protatonce. He engineered the sale of Novosom's assets to Marina Biotech (MRNA). Mr. Papatheodorou received his undergraduate education at Ithaca College, NY and his graduate education at Cornell University, NY.
Insufficient data for Elias to compare compensation growth.
Insufficient data for Elias to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Genkyotex management team is about average.
CEO & Director
Founder & Member of Scientific Advisory Board
Vice President Finance & Administration
Chief Scientific Officer
Chief Medical Officer & Executive VP
Consultant of Knowledge Management & Computational Chemistry
Genkyotex S.A., a biopharmaceutical company, develops oral small molecule NOX therapeutics. Its platform enables the identification of orally available small-molecules that selectively inhibit NOX enzymes amplifying various disease processes, such as fibrosis, inflammation, pain processing, cancer development, and neurodegeneration. The company’s lead product candidate is GKT831, a NOX1 and NOX4 inhibitor, which is evaluated in a Phase II clinical trial in primary biliary cholangitis, a fibrotic orphan disease, and in an investigator-initiated Phase II clinical trial in type 1 diabetes and kidney disease. Its second product candidate, GKT771, is a NOX1 inhibitor, which is undergoing preclinical testing targeting various pathways in angiogenesis, pain processing, and inflammation. The company’s research programs include brain penetrant NOX inhibitors to address CNS disorders and NOX inhibitors in oncology. Genkyotex S.A. has a partnership with Serum Institute of India Ltd for the development of prophylactic vaccines. The company was founded in 2006 and is based in Saint Julien En Genevois, France.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.